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Abstract
In recent years, Scedosporium species have been more commonly recognized from se-
vere, difficult-to-treat human infections, such as upper respiratory tract and pulmonary
infections. To select an appropriate therapeutic approach for these infections is challeng-
ing, because of the commonly observed resistance of the causative agents to several
antifungal drugs. Therefore, to find a novel strategy for the treatment of pulmonary
Scedosporium infections the in vitro antifungal effect of a mucolytic agent, N-acetyl-L-
cysteine and its in vitro combinations with conventional antifungals were investigated.
Synergistic and indifferent interactions were registered in 23 and 13 cases, respectively.
Antagonism was not revealed between the compounds.
Key words: Scedosporium spp., pulmonary infection, N-acetyl-L-cysteine, antifungal activity, drug combinations,
synergistic interaction.
Introduction
Members of the genus Scedosporium are known to cause
localized infections in immunocompetent hosts or invasive
mycoses in immunocompromised patients. Scedosporium
apiospermum and related species may form fungus balls
in patients with previous or underlying cavitary lung dis-
eases (e.g., tuberculosis); they are frequent colonizers of
the airways of cystic fibrosis patients and can cause Sce-
dosporium pneumonia in otherwise healthy hosts.1,2 As
their symptoms and clinical manifestations can be sim-
ilar to aspergillosis, the real incidence and clinical im-
portance of these pathogens may be underestimated.2 In
a recent survey involving fungal samples from 29 hos-
pitals of Spain, Scedosporium species proved to be the
second most frequently isolated filamentous fungi after
Aspergilli.3 Furthermore, their poor susceptibility to clin-
ically used antifungals makes the Scedosporium infections
difficult to treat.1 Therefore, finding new agents with a
better antifungal activity against these species is urgently
needed.
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N-acetyl-L-cysteine (NAC) has an excellent antioxidant
activity and it is a commonly used mucolytic drug to treat
acute infections of the respiratory tract.4 The in vitro in-
hibitory effect of NAC has been previously proven against
certain agriculturally and medically important filamentous
fungal pathogens.5,6
In this study, we evaluated the in vitro antifungal effect
of NAC against nine Scedosporium isolates and its combi-
nation with conventional antifungal agents.
Materials and methods
Pseudallescheria angusta (CBS 254.72 from sewage),
Pseudallescheria ellipsoidea (CBS 301.79 from dung), Sce-
dosporium boydii (previously known as Pseudallescheria
boydii, CBS 120157, CBS 117410, CBS 117432 from
human lung, soil, and sputum, respectively), and Sce-
dosporium aurantiacum (CBS 136046, CBS 136047, CBS
136049, CBS 116910 from human lung, soil, soil and
wound exudate, respectively) were involved in this study.
Susceptibility tests were performed in accordance with the
slightly modified instructions of the CLSI M38-A2 broth
microdilution method,7 in triplicates. Modifications re-
lated to stock solution and inoculum preparation were
detailed previously.8 The final drug concentrations in the
tests ranged from 64 to 1024 μg ml−1. In some cases,
where the MICs of NAC (Sigma-Aldrich, USA) could
not be determined in this concentration range, further
higher concentrations (2048-8192 μg ml−1) were also
tested.
Drug interactions were investigated between NAC and
four conventional antifungal agents (i.e., amphotericin B,
AMB; caspofungin, CSP; terbinafine, TRB; and voricona-
zole, VRC) representing a polyene, an echionocandin, an al-
lylamine, and an azole antimycotic, using the checkerboard
microdilution method.9 Serial twofold dilutions were pre-
pared in a final concentration range of 64–4096μg ml−1 for
NAC, and 0.125-128 μg ml−1 for antifungal drugs. Frac-
tional inhibitory concentration indexes (FICI) were calcu-
lated as described before.10
Results
Susceptibility of clinical Scedosporium spp. to NAC and
its combination with antifungal drugs has not been inves-
tigated before. This paper provides the first MIC dataset
about it. All the MIC values of NAC were in the range
of 1024–8192 μg ml−1 (Table 1). Environmental isolates
proved to be relatively less susceptible to NAC with a MIC
range of 1024–8192 μg ml−1 compared to clinical isolates
(MIC range: 1024–2048 μg ml−1). Our results are com-
parable with previously reported data against other fun-
gal species. The complete growth inhibition of Mucoralean
fungi by cysteine and its derivatives was observed at a con-
centration of 10 mmol l−1,6 which means approx. 1200–
2000 μg ml−1. In another study, the MICs of NAC against
Aspergillus and Fusarium spp. were in the range of 6000–
25000 μg ml−1.5 In contrast, in case of Scedosporium spp.,
we observed a lower MIC range.
Results of combination tests are summarized in Table 1.
The MIC range of NAC alone reduced in the combination
tests to 64–2048 μg ml−1 by AMB, to 64–1024 μg ml−1
by CSP, 128–2048 μg ml−1 by TRB, and 64–512 μg ml−1
by VRC. A more prominent decrease was detected in the
MICs of antifungal agents when they were combined with
NAC. When applied alone, the MIC ranges of AMB, CSP,
TRB, VRC were 8–128 μg ml−1, 32–64 μg ml−1, 128 μg
ml−1, and 8–64 μg ml−1, respectively. While, in combi-
nation with NAC the MIC ranges of AMB, CSP, TRB,
and VRC could be decreased to 0.125–64 μg ml−1, 0.125–
16 μg ml−1, 0.5–128 μg ml−1, and 0.125–64 μg ml−1, re-
spectively. Between NAC and CSP, synergy was detected at
seven isolates. While at NAC+AMB and NAC+TRB com-
binations, synergy was observed against six out of the nine
strains. BetweenNAC and VRC, synergismwas observed in
four cases (Table 1). Antagonism was not detected between
the investigated drugs.
The idea behind combinational antifungal therapy is im-
proving the antifungal effect and reducing the dosage of
antifungals to avoid side-effects with the simultaneous ap-
plication of two or more antifungal drugs. In our study,
the MIC values of antifungals in combination with NAC
could be decreased to their achievable plasma concentra-
tion in several cases.11–14 The MICs of NAC were also
decreased in the combination tests; the lowest MIC value
(64 μg ml−1) is still higher than its maximal plasma con-
centration, which is between 2.6–48.96 μg ml−1 depending
on the dosage and the route of administration.15–17 Apart
from this, synergisms between antifungal agents and NAC
suggest that it would be worthwhile to investigate the in
vivo efficacy of these combinations, and to determine the
clinical relevance of our results.
Conclusion
Although previous in vitro susceptibility data on the combi-
nations of cysteine derivatives and conventional antifungal
drugs are not available in the literature, another aspect of
the co-administration was investigated and reported by Lee
et al.18 It was demonstrated that, in cancer or AIDS pa-
tients where itraconazole (ITC) metabolism is impaired due
to the altered expression of cytochrome P450 (CYP), oral
cysteine administration could restore the normal CYP and
thus the ITC level, too.18 This also supports that (beside the
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direct inhibitory effect on fungi) NAC has other beneficial
properties, which may improve the efficacy of a potential
antifungal therapy and/or reduce the side effects caused by
azoles. According to previous studies, NAC is able to in-
crease the antioxidant capacity of the lung and enhance the
antimicrobial activity of macrophages against Candida
spp.17,19 Furthermore, in combination with antifungal ther-
apy, the administration of NAC alleviated oxidative stress
and lung injury associated with invasive pulmonary as-
pergillosis in a neutropenic mice model.20
Our results together with the aforementioned consider-
ations arise the need of further in vivo studies to clarify
the efficacy and applicability of NAC in the treatment of
pulmonary Scedosporium infections.
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